

NZX

Ransomed, Healed, Restored, Forgiven?

JAMIE FOULKES

jamie.foulkes@forsythbarr.co.nz
+64 4 914 2217

OUTPERFORM

NZX reported a stronger than expected FY20 result with a good performance from every division. This was driven by impressive organic revenue growth offsetting higher than anticipated costs. The company has invested heavily in additional headcount and IT infrastructure during FY20, in light of outages occurring during the year and we expect to see continued investment into FY21. We recognise the largely unknown nature of these infrastructure investments during the year ahead, however, first time FY21 EBITDA guidance appears conservative at this stage. We remain attracted to NZX's diversified revenue streams, stable balance sheet, organic growth in the Smartshares business and momentum building in both the Issuer Relationships and Wealth Technologies divisions, while the business continues to screen well from an ESG context.

| NZX Code | NZX | Financials: Dec/ | 20A | 21E | 22E | 23E | Valuation (x) | 20A | 21E | 22E | 23E |
|--------------------|-------------------|------------------------------|------|------|------|------|-------------------|------|------|------|------|
| Share price | NZ\$2.00 | NPAT* (NZ\$m) | 17.6 | 17.6 | 20.4 | 24.8 | PE | 31.9 | 32.0 | 27.5 | 22.6 |
| Target price | NZ\$2.16 | EPS* (NZc) | 6.3 | 6.3 | 7.3 | 8.8 | EV/EBIT | 21.1 | 21.0 | 18.3 | 15.2 |
| Risk rating | Medium | EPS growth* (%) | 18.8 | -0.4 | 16.4 | 21.5 | EV/EBITDA | 16.0 | 15.6 | 14.2 | 12.2 |
| Issued shares | 277.2m | DPS (NZc) | 6.1 | 6.1 | 7.0 | 8.5 | Price / NTA | n/a | n/a | n/a | n/a |
| Market cap | NZ\$554m | Imputation (%) | 100 | 100 | 100 | 100 | Cash div yld (%) | 3.1 | 3.1 | 3.5 | 4.3 |
| Avg daily turnover | 334.9k (NZ\$506k) | *Based on normalised profits | | | | | Gross div yld (%) | 4.2 | 4.2 | 4.9 | 5.9 |

What's changed?

- **Earnings:** FY21 EBITDA increased from NZ\$34.8m to NZ\$35.0m (+0.6%), FY21 CAPEX increased from NZ\$10m to NZ\$13m.
- **Target price:** Decreased from NZ\$2.25 to NZ\$2.16 (-4%) driven by changes to our cost of capital assumptions.

FY21 guidance appears conservative despite largely unknown operational expenditure

NZX has guided FY21 EBITDA of between NZ\$31.5m and NZ\$35.5m (mid-point NZ\$33.5m) which in our view appears conservative. We raise our FY21 EBITDA forecasts marginally to NZ\$35m and see upside risk given 1) momentum building in capital raised in the Issuer Relationships division and 2) a pipeline of potential contract wins in the Wealth Technologies business.

2021 deliverable targets broadly in line with expectations

NZX's 2021 deliverable targets delivered few surprises with the FY23 EBITDA target of NZ\$42–NZ\$54m remaining unchanged.

- Issuer Relationships capital raised target was set to NZ\$10.0bn against our forecasts of NZ\$10.8bn
- Secondary Markets value traded expected is to be NZ\$45bn vs our forecast of NZ\$46.2bn
- Funds Under Management growth target of +14.0% vs our expectations of 14.8%
- Wealth Technologies FUA is anticipated to reach NZ\$10bn for FY21 vs our assumption of NZ\$10.2bn

Short term cost elevation provides little impact to valuation

We make changes to our risk free rate (from 1.3% to 2.3%) and market risk premium (from 6.0% to 5.5%), consistent with our strategy report, *Still a One Way Bet? – Updated WACC Assumptions*, published 12 February 2021. Our WACC moves from 6.9% to 7.1%, decreasing our valuation from NZ\$2.25 to NZ\$2.16. The increase in IT and infrastructure costs seen across FY20 and FY21 create little impact to our valuation due to its one-off nature.

NZX Ltd (NZX)

Priced as at 17 Feb 2021 (NZ\$)

2.00

12-month target price (NZ\$)*

2.16

Expected share price return

8.0%

Net dividend yield

3.1%

Estimated 12-month return

11.1%

Spot valuations (NZ\$)

1.DCF

2.16

2.n/a

n/a

3.n/a

n/a

Key WACC assumptions

Risk free rate

2.30%

Equity beta

0.95

WACC

7.1%

Terminal growth

1.5%

DCF valuation summary (NZ\$m)

Total firm value

588

(Net debt)/cash

14

Less: Capitalised operating leases

(28)

Value of equity

574

Profit and Loss Account (NZ\$m)

| | 2019A | 2020A | 2021E | 2022E | 2023E |
|-------------------------------|-------------|-------------|-------------|-------------|-------------|
| Sales revenue | 69.5 | 78.4 | 80.3 | 88.5 | 97.7 |
| Normalised EBITDA | 31.4 | 34.4 | 35.0 | 38.8 | 45.1 |
| Depreciation and amortisation | (8.6) | (8.3) | (8.9) | (8.7) | (8.8) |
| Normalised EBIT | 22.8 | 26.1 | 26.1 | 30.1 | 36.2 |
| Net interest | (2.0) | (1.9) | (1.5) | (1.5) | (1.5) |
| Associate income | 0 | 0 | 0 | 0 | 0 |
| Tax | (5.9) | (7.0) | (7.0) | (8.2) | (9.9) |
| Minority interests | 0 | 0 | 0 | 0 | 0 |
| Normalised NPAT | 14.6 | 17.6 | 17.6 | 20.4 | 24.8 |
| Abnormals/other | 0 | 0 | 0 | 0 | 0 |
| Reported NPAT | 14.6 | 17.6 | 17.6 | 20.4 | 24.8 |
| Normalised EPS (cps) | 5.3 | 6.3 | 6.3 | 7.3 | 8.8 |
| DPS (cps) | 6.1 | 6.1 | 6.1 | 7.0 | 8.5 |

Growth Rates

| | 2019A | 2020A | 2021E | 2022E | 2023E |
|---------------------|-------|-------|-------|-------|-------|
| Revenue (%) | 13.7 | 12.8 | 2.3 | 10.3 | 10.4 |
| EBITDA (%) | 17.4 | 9.7 | 1.8 | 10.9 | 16.1 |
| EBIT (%) | 16.8 | 14.6 | 0.0 | 15.3 | 20.3 |
| Normalised NPAT (%) | 23.8 | 20.1 | -0.2 | 16.4 | 21.5 |
| Normalised EPS (%) | 21.8 | 18.8 | -0.4 | 16.4 | 21.5 |
| Ordinary DPS (%) | 0.0 | 0.0 | 0.0 | 14.8 | 21.4 |

Cash Flow (NZ\$m)

| | 2019A | 2020A | 2021E | 2022E | 2023E |
|--|-------------|-------------|--------------|-------------|-------------|
| EBITDA | 31.4 | 34.4 | 35.0 | 38.8 | 45.1 |
| Working capital change | 0.2 | 2.1 | (0.1) | (0.3) | (0.4) |
| Interest & tax paid | (7.8) | (9.0) | (8.5) | (9.7) | (11.4) |
| Other | 1.1 | 3.7 | 0 | 0 | 0 |
| Operating cash flow | 24.8 | 31.2 | 26.4 | 28.8 | 33.3 |
| Capital expenditure | (8.3) | (10.0) | (13.0) | (10.0) | (10.1) |
| (Acquisitions)/divestments | (0.0) | 0 | 0 | 0 | 0 |
| Other | (1.3) | (1.5) | 0 | 0 | 0 |
| Funding available/(required) | 15.2 | 19.8 | 13.4 | 18.8 | 23.2 |
| Dividends paid | (12.8) | (14.8) | (17.0) | (18.4) | (22.3) |
| Equity raised/(returned) | 0 | 0 | 0 | 0 | 0 |
| (Increase)/decrease in net debt | 2.4 | 5.0 | (3.6) | 0.4 | 0.8 |

Balance Sheet (NZ\$m)

| | 2019A | 2020A | 2021E | 2022E | 2023E |
|------------------------------|--------------|--------------|--------------|--------------|--------------|
| Working capital | 5.2 | 3.2 | 3.2 | 3.6 | 3.9 |
| Fixed assets | 2.6 | 2.1 | 1.6 | 1.3 | 1.1 |
| Intangibles | 67.7 | 71.1 | 76.6 | 79.0 | 81.1 |
| Right of use asset | 5.8 | 5.1 | 4.4 | 4.0 | 3.7 |
| Other assets | 79.7 | 104.7 | 104.7 | 104.7 | 104.7 |
| Total funds employed | 161.0 | 186.2 | 190.6 | 192.5 | 194.5 |
| Net debt/(cash) | (8.9) | (13.9) | (10.3) | (10.7) | (11.5) |
| Lease liability | 7.2 | 5.7 | 5.4 | 5.1 | 4.8 |
| Other liabilities | 98.8 | 126.7 | 126.7 | 126.6 | 126.5 |
| Shareholder's funds | 63.9 | 67.7 | 68.8 | 71.5 | 74.8 |
| Minority interests | 0 | 0 | 0 | 0 | 0 |
| Total funding sources | 161.0 | 186.2 | 190.6 | 192.5 | 194.5 |

* Forsyth Barr target prices reflect valuation rolled forward at cost of equity less the next 12-months dividend

Valuation Ratios

| | 2019A | 2020A | 2021E | 2022E | 2023E |
|--------------------------|-------|-------|-------|-------|-------|
| EV/EBITDA (x) | 17.4 | 15.8 | 15.5 | 14.0 | 12.1 |
| EV/EBIT (x) | 24.0 | 20.8 | 20.8 | 18.1 | 15.0 |
| PE (x) | 37.9 | 31.9 | 32.0 | 27.5 | 22.6 |
| Price/NTA (x) | n/a | n/a | n/a | n/a | n/a |
| Free cash flow yield (%) | 3.0 | 3.8 | 2.4 | 3.4 | 4.2 |
| Net dividend yield (%) | 3.1 | 3.1 | 3.1 | 3.5 | 4.3 |
| Gross dividend yield (%) | 4.2 | 4.2 | 4.2 | 4.9 | 5.9 |

Capital Structure

| | 2019A | 2020A | 2021E | 2022E | 2023E |
|---------------------------|-------|-------|-------|-------|-------|
| Interest cover EBIT (x) | 11.7 | 13.5 | 17.1 | 20.1 | 24.5 |
| Interest cover EBITDA (x) | n/a | n/a | n/a | n/a | n/a |
| Net debt/ND+E (%) | -16.1 | -25.8 | -17.5 | -17.6 | -18.3 |
| Net debt/EBITDA (x) | n/a | n/a | n/a | n/a | n/a |

Key Ratios

| | 2019A | 2020A | 2021E | 2022E | 2023E |
|------------------------------|-------|-------|-------|-------|-------|
| Return on assets (%) | 10.7 | 10.6 | 10.5 | 12.0 | 14.2 |
| Return on equity (%) | 22.9 | 26.0 | 25.5 | 28.6 | 33.2 |
| Return on funds employed (%) | 30.7 | 35.4 | 32.6 | 36.0 | 41.6 |
| EBITDA margin (%) | 45.1 | 43.9 | 43.6 | 43.9 | 46.1 |
| EBIT margin (%) | 32.7 | 33.3 | 32.5 | 34.0 | 37.1 |
| Capex to sales (%) | 11.9 | 12.7 | 16.2 | 11.3 | 10.4 |
| Capex to depreciation (%) | 416 | 456 | 671 | 629 | 738 |
| Imputation (%) | 100 | 100 | 100 | 100 | 100 |
| Pay-out ratio (%) | 115 | 97 | 98 | 96 | 96 |

Operating Performance

Revenue (NZ\$m)

| | 2019A | 2020A | 2021E | 2022E | 2023E |
|----------------------|-------------|-------------|-------------|-------------|-------------|
| Core markets | 54.5 | 58.7 | 56.9 | 59.7 | 60.8 |
| Funds services | 14.6 | 16.1 | 20.1 | 25.5 | 33.5 |
| Corporate | 0.5 | 0.2 | 0.1 | 0.1 | 0.1 |
| Total revenue | 69.5 | 75.0 | 77.1 | 85.3 | 94.4 |

Revenue % chg

| | 2019A | 2020A | 2021E | 2022E | 2023E |
|----------------------|-------------|-------------|-------------|--------------|--------------|
| Core markets | 4.9% | 7.7% | -3.0% | 4.8% | 1.9% |
| Funds services | 16.4% | 10.4% | 24.7% | 26.8% | 31.6% |
| Total revenue | 7.9% | 7.8% | 2.8% | 10.6% | 10.7% |

EBITDA (NZ\$m)

| | 2019A | 2020A | 2021E | 2022E | 2023E |
|---------------------|-------------|-------------|-------------|-------------|------------|
| Core markets | 41.2 | 0.0 | 0.0 | 0.0 | 0.0 |
| Funds services | 5.2 | 5.3 | 8.0 | 11.2 | 17.8 |
| Corporate | (15.0) | (14.9) | (14.0) | (15.3) | (16.0) |
| Total EBITDA | 31.4 | -9.5 | -6.0 | -4.1 | 1.8 |

EBITDA % chg

| | 2019A | 2020A | 2021E | 2022E | 2023E |
|---------------------|-------------|----------------|---------------|---------------|----------------|
| Core markets | 4.2% | -100.0% | #DIV/0! | #DIV/0! | #DIV/0! |
| Funds services | 8.6% | 3.2% | 50.3% | 40.2% | 58.3% |
| Total EBITDA | 9.8% | -130.4% | -36.7% | -32.0% | -143.6% |


FY20 Result summary

NZX's impressive FY20 result demonstrated clear progress made under the current management team, with the business gathering momentum across all divisions. This was evident given the reported FY20 EBITDA of NZ\$34.4m, ahead of our forecast NZ\$33.6m.

Within the market divisions, the Issuer Relationships division's target for capital raises during the year exceeded expectations (NZ\$17.63bn vs NZ\$9.5bn), predominantly driven by increased secondary capital raises in light of COVID-19 restructuring. The Secondary Markets division reported total value traded to be NZ\$53.7bn against a target set of NZ\$38.6bn, with value traded remaining elevated during the second half of the year. The data division was bolstered by total terminal and licence usage increasing by a monthly average of +14% during FY20 against the prior year. Funds Under Management saw an increase of +28% for the year against a target of +14% while the Wealth Technologies division saw FUA reach NZ\$7.2bn against prior company expectations of NZ\$5-6bn.


Operating costs during FY20 were higher than anticipated (NZ\$44.0m vs our forecast NZ\$42.5m) with a higher degree of infrastructure and IT costs falling into FY20 (over FY21) than we previously expected. Depreciation and amortisation were marginally lower than expectations (NZ\$8.2m vs NZ\$8.8m), driving a reported FY20 NPAT of NZ\$17.6m against our forecast of NZ\$16.4m.

Figure 1. Revenue, EBITDA, margin FY14A to FY23E



Source: Forsyth Barr analysis

Figure 2. FY20 Revenue split by division



Source: Forsyth Barr analysis


Changes to forecasts

Decreased revenue reflects lower forecast audit revenue in the Data division, a slight increase in fee compression in the Smartshares business and lower average bps generated from FUA in the Wealth Technologies division (6.2bps decreased to 4.9bps). We adjust our earnings forecasts to include slightly lower costs in FY21 (higher than expected in FY20) but increase our FY21 CAPEX from NZ\$10m to NZ\$13m.

Figure 3. Changes to forecasts FY21E–FY23E

| (NZ\$'000) | Old | FY21E New | Chg | Old | FY22E New | Chg | FY23E New |
|-----------------|--------|--------------|-------|--------|--------------|-------|--------------|
| Revenue | 82,096 | 80,259 | -2.2% | 91,805 | 88,504 | -3.6% | 97,743 |
| EBITDA | 34,795 | 35,015 | 0.6% | 39,992 | 38,825 | -2.9% | 45,067 |
| EBITDA margin % | 42.4% | 43.6% | 1.2% | 43.6% | 43.9% | 0.3% | 46.1% |
| NPAT | 17,591 | 17,550 | -0.2% | 21,411 | 20,425 | -4.6% | 24,813 |
| EPS (cent) | 6.3 | 6.3 | -0.2% | 7.7 | 7.3 | -4.6% | 8.9 |
| DPS (cent) | 6.1 | 6.1 | 0.0% | 7.0 | 7.0 | 0.0% | 8.5 |

Source: Forsyth Barr analysis

Figure 4. Price performance


Source: Forsyth Barr analysis

Figure 5. Substantial shareholders

| Shareholder | Latest Holding |
|-----------------------------------|----------------|
| Aberdeen Asset Management Limited | 9.1% |


Source: NZX, Forsyth Barr analysis, NOTE: based on SPH notices only

Figure 6. International valuation comparisons


| Company | Code | Price | Mkt Cap (m) | PE 2021E | PE 2022E | EV/EBITDA 2021E | EV/EBITDA 2022E | EV/EBIT 2021E | EV/EBIT 2022E | Cash Yld 2022E |
|--|---------|------------|-------------|----------|----------|-----------------|-----------------|---------------|---------------|----------------|
| (metrics re-weighted to reflect NZX's balance date - December) | | | | | | | | | | |
| NZX | NZX NZ | NZ\$2.00 | NZ\$554 | 32.0x | 27.5x | 15.4x | 13.9x | 20.7x | 18.0x | 3.5% |
| ASX | ASX AT | A\$70.89 | A\$13,724 | 28.5x | 27.8x | 18.9x | 18.1x | 20.5x | 20.0x | 3.2% |
| CME GROUP INC | CME US | US\$187.21 | US\$67,207 | 28.4x | 26.3x | 21.8x | 20.1x | 22.0x | 20.4x | 3.6% |
| NASDAQ INC | NDAQ US | US\$143.12 | US\$23,476 | 22.8x | 21.1x | 15.9x | 15.1x | 18.3x | n/a | 1.5% |
| LONDON STOCK EXCHANGE GROUP | LSE LN | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| DEUTSCHE BOERSE AG | DB1 GR | €138.90 | €26,306 | 21.1x | 19.2x | 13.9x | 12.6x | 16.2x | 14.5x | 2.5% |
| INTERCONTINENTAL EXCHANGE IN | ICE US | US\$111.86 | US\$62,827 | 22.9x | 21.3x | 18.3x | 17.4x | 23.7x | 20.7x | 1.3% |
| TMX GROUP | X CN | C\$126.27 | C\$7,156 | 19.7x | 18.2x | 14.1x | 13.2x | 16.8x | 15.3x | 2.4% |
| HONG KONG EXCHANGES & CLEAR | 388 HK | HK\$548.00 | HK\$694,775 | >50x | 48.7x | 30.2x | 24.0x | 32.9x | 25.6x | 1.8% |
| SINGAPORE EXCHANGE | SGX SP | S\$10.02 | S\$10,734 | 23.2x | 22.5x | 15.9x | 15.4x | 18.3x | 17.6x | 3.4% |
| Compco Average: | | | | 23.8x | 25.6x | 18.6x | 17.0x | 21.1x | 19.2x | 2.5% |
| NZX Relative: | | | | 35% | 7% | -17% | -18% | -2% | -6% | 42% |

EV = Current Market Cap + Actual Net Debt

Source: *Forsyth Barr analysis, Bloomberg Consensus, Compco metrics re-weighted to reflect headline (NZX) companies fiscal year end

Figure 7. Consensus EPS momentum (NZ\$)


Source: Forsyth Barr analysis

Figure 8. One year forward PE (x)


Source: Forsyth Barr analysis

Analyst certification: The research analyst(s) primarily responsible for the preparation and content of this publication ("**Analysts**") are named on the first page of this publication. Each such Analyst certifies (other than in relation to content or views expressly attributed to another analyst) that (i) the views expressed in this publication accurately reflect their personal views about each issuer and financial product referenced and were prepared in an independent manner, including with respect to Forsyth Barr Limited and its related companies; and (ii) no part of the Analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that Analyst in this report.

Analyst holdings: The following Analyst(s) have a threshold interest in the financial products referred to in this publication: N/A. For these purposes, a threshold interest is defined as being a holder of more than \$50,000 in value or 1% of the financial products on issue, whichever is the lesser.

Ratings distributions: As at 16 Feb 2021, Forsyth Barr's research ratings were distributed as follows:

| OUTPERFORM | NEUTRAL | UNDERPERFORM |
|-------------------|----------------|---------------------|
| 46.2% | 36.5% | 17.3% |

Forsyth Barr's research ratings are OUTPERFORM, NEUTRAL, and UNDERPERFORM. The ratings are relative to our other equity security recommendations across our New Zealand market coverage and are based on risk-adjusted Estimated Total Returns for the securities in question. Risk-adjusted Estimated Total Returns are calculated from our assessment of the risk profile, expected dividends and target price for the relevant security.

Disclosure: Forsyth Barr Limited and its related companies (and their respective directors, officers, agents and employees) ("Forsyth Barr") may have long or short positions or otherwise have interests in the financial products referred to in this publication, and may be directors or officers of, and/or provide (or be intending to provide) investment banking or other services to, the issuer of those financial products (and may receive fees for so acting). Forsyth Barr is not a registered bank within the meaning of the Reserve Bank of New Zealand Act 1989. Forsyth Barr may buy or sell financial products as principal or agent, and in doing so may undertake transactions that are not consistent with any recommendations contained in this publication. Other Forsyth Barr business units may hold views different from those in this publication; any such views will generally not be brought to your attention. Forsyth Barr confirms no inducement has been accepted from the issuer(s) that are the subject of this publication, whether pecuniary or otherwise, in connection with making any recommendation contained in this publication. In preparing this publication, non-financial assistance (for example, access to staff or information) may have been provided by the issuer(s) being researched.

Investment banking engagements: Other than confidential engagements, Forsyth Barr has not within the past 12 months been engaged to provide investment banking services to the issuer that is the subject of this publication. For information about whether Forsyth Barr has within the past 12 months been engaged to provide investment banking services to any other issuer referred to in this publication, please refer to the most recent research report for that issuer's financial products.

Not personalised financial advice: The recommendations and opinions in this publication do not take into account your personal financial situation or investment goals. The financial products referred to in this publication may not be suitable for you. If you wish to receive personalised financial advice, please contact your Forsyth Barr Investment Adviser. The value of financial products may go up and down and investors may not get back the full (or any) amount invested. Past performance is not necessarily indicative of future performance. Disclosure statements for Forsyth Barr Investment Advisers are available on request and free of charge.

Disclaimer: This publication has been prepared in good faith based on information obtained from sources believed to be reliable and accurate. However, that information has not been independently verified or investigated by Forsyth Barr. Forsyth Barr does not make any representation or warranty (express or implied) that the information in this publication is accurate or complete, and, to the maximum extent permitted by law, excludes and disclaims any liability (including in negligence) for any loss which may be incurred by any person acting or relying upon any information, analysis, opinion or recommendation in this publication. Forsyth Barr does not undertake to keep current this publication; any opinions or recommendations may change without notice to you. Any analyses or valuations will typically be based on numerous assumptions; different assumptions may yield materially different results. Nothing in this publication should be construed as a solicitation to buy or sell any financial product, or to engage in or refrain from doing so, or to engage in any other transaction. This publication is not intended to be distributed or made available to any person in any jurisdiction where doing so would constitute a breach of any applicable laws or regulations or would subject Forsyth Barr to any registration or licensing requirement within such jurisdiction.

Terms of use: Copyright Forsyth Barr Limited. You may not redistribute, copy, revise, amend, create a derivative work from, extract data from, or otherwise commercially exploit this publication in any way. By accessing this publication via an electronic platform, you agree that the platform provider may provide Forsyth Barr with information on your readership of the publications available through that platform.